Free Pharma Reference
GLP-1 Titration Schedules
FDA-approved dose-escalation reference data for semaglutide, tirzepatide, and liraglutide products — escalation intervals, maintenance doses, and trial-design context for pharma, medical affairs, and clinical development teams.
Quick Answer
GLP-1 receptor agonists and dual GIP/GLP-1 agents require gradual dose escalation to limit GI adverse events during initiation. This reference summarizes FDA label titration schedules for semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) — escalation intervals, maintenance doses, and pivotal trial comparators for protocol design and medical affairs teams.
Approved Product Comparison
Summary of FDA label titration schedules as of June 2026. Verify against current prescribing information before protocol or medical writing decisions.
| Product (INN) | Indication | Starting Dose | Escalation Steps | Maintenance Dose | Frequency |
|---|---|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes | 0.25 mg SC | 0.25 mg × 4 wk → 0.5 mg; optional → 1 mg → 2 mg (each × 4 wk) | 0.5, 1, or 2 mg SC weekly | Once weekly |
| Wegovy (semaglutide) | Chronic weight management | 0.25 mg SC | 0.25 → 0.5 → 1.0 → 1.7 mg (each × 4 wk) | 2.4 mg SC weekly | Once weekly |
| Rybelsus (oral semaglutide) | Type 2 diabetes | 3 mg PO | 3 mg × 30 d → 7 mg × 30 d | 14 mg PO daily | Once daily (fasting) |
| Mounjaro (tirzepatide) | Type 2 diabetes | 2.5 mg SC | +2.5 mg every 4 wk: 5 → 7.5 → 10 → 12.5 → 15 mg | 5–15 mg SC weekly | Once weekly |
| Zepbound (tirzepatide) | Chronic weight management | 2.5 mg SC | +2.5 mg every 4 wk: 5 → 7.5 → 10 → 12.5 → 15 mg | 5–15 mg SC weekly | Once weekly |
| Victoza (liraglutide) | Type 2 diabetes | 0.6 mg SC | 0.6 mg × 1 wk → 1.2 mg daily; optional → 1.8 mg | 1.2 or 1.8 mg SC daily | Once daily |
| Saxenda (liraglutide) | Chronic weight management | 0.6 mg SC | +0.6 mg weekly × 5 wk: 1.2 → 1.8 → 2.4 → 3.0 mg | 3.0 mg SC daily | Once daily |
Semaglutide — Ozempic & Wegovy
Mechanism: GLP-1 receptor agonist (acylated peptide, 94% homology to native GLP-1, albumin binding extends half-life to ~165 hours enabling weekly dosing).
Ozempic (T2D): Initiate at 0.25 mg SC once weekly for 4 weeks (tolerability priming — sub-therapeutic for glycemic effect). Increase to 0.5 mg maintenance. If additional glycemic control needed, escalate to 1 mg after ≥4 weeks at 0.5 mg, then optionally to 2 mg after ≥4 weeks at 1 mg.
Wegovy (obesity): Five-step 16-week escalation to 2.4 mg: 0.25 mg (wk 1–4) → 0.5 mg (wk 5–8) → 1.0 mg (wk 9–12) → 1.7 mg (wk 13–16) → 2.4 mg maintenance. Label permits extending any step by 4 weeks for GI intolerance. Pivotal STEP trials evaluated 2.4 mg after this titration.
| Weeks | Ozempic (T2D) | Wegovy (obesity) |
|---|---|---|
| 1–4 | 0.25 mg SC QW | 0.25 mg SC QW |
| 5–8 | 0.5 mg SC QW | 0.5 mg SC QW |
| 9–12 | 0.5 mg (maint.) or → 1 mg | 1.0 mg SC QW |
| 13–16 | — | 1.7 mg SC QW |
| 17+ | 0.5–2 mg SC QW | 2.4 mg SC QW |
Tirzepatide — Mounjaro & Zepbound
Mechanism: GIP and GLP-1 receptor dual agonist. Same molecule and titration schema for T2D (Mounjaro) and obesity (Zepbound) indications.
Escalation: Start 2.5 mg SC once weekly × 4 weeks, then increase by 2.5 mg increments every 4 weeks to maximum 15 mg. SURPASS (T2D) and SURMOUNT (obesity) pivotal trials evaluated 5, 10, and 15 mg maintenance doses after label-equivalent titration.
| Weeks | Dose (SC once weekly) |
|---|---|
| 1–4 | 2.5 mg |
| 5–8 | 5.0 mg |
| 9–12 | 7.5 mg |
| 13–16 | 10 mg |
| 17–20 | 12.5 mg |
| 21+ | 15 mg (maximum) |
Each step may be extended by 4 weeks per label if GI adverse events occur. For protocol design, note that reaching 15 mg requires up to 20 weeks — longer than semaglutide Wegovy's 16-week escalation to 2.4 mg.
Liraglutide — Victoza & Saxenda
Mechanism: GLP-1 receptor agonist with ~97% homology to native GLP-1, half-life ~13 hours requiring daily injection. First-generation approved incretin; largely superseded by weekly agents but remains relevant for biosimilar and generic competitive landscapes.
Victoza (T2D): 0.6 mg SC daily × 1 week → 1.2 mg daily maintenance. May increase to 1.8 mg if additional glycemic control needed.
Saxenda (obesity): Weekly 0.6 mg increments over 5 weeks: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg daily maintenance. SCALE pivotal trials used 3.0 mg after this titration.
Oral Semaglutide — Rybelsus
Formulation note: Oral semaglutide uses SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) as an absorption enhancer. Bioavailability is ~0.4–1%, requiring strict fasting administration conditions distinct from injectable semaglutide.
Titration: 3 mg PO daily × 30 days (tolerability only — not glycemic-effective) → 7 mg PO daily × 30 days → 14 mg PO daily maintenance. Take on empty stomach with ≤120 mL (4 oz) plain water only; wait ≥30 minutes before first food, beverage, or other oral medication.
Relevance for pharma teams: Oral formulation titration uses 30-day (not 4-week) intervals and a non-therapeutic starting dose — important for trial visit schedules, patient-support program design, and competitive differentiation versus weekly injectables.
Titration Rationale — GI Tolerability, Adherence & Trial Design
GI tolerability: Nausea is the most common AE across all GLP-1 RA classes, with incidence peaking during dose escalation. Gradual titration reduces peak incidence and severity by allowing receptor-level adaptation. FDA labels embed this rationale with explicit permission to extend escalation intervals.
Adherence and persistence: Real-world data consistently show highest discontinuation in the first 12 weeks — coinciding with titration. Patient-support programs, HCP education on expected GI events, and flexible escalation are standard medical affairs strategies. Persistence metrics should be analyzed post-titration, not from day 1.
Clinical trial design implications:
- Randomization timing: most pivotal trials randomize at initiation and titrate both arms, or use a run-in period before the primary endpoint assessment window.
- Primary endpoint timing: efficacy readouts (e.g., weight change at 72 weeks) occur after titration completion — early timepoints reflect tolerability, not maintenance-dose efficacy.
- Rescue criteria and dropout: protocols should pre-specify whether failure to tolerate titration counts as AE-related discontinuation vs. non-responder.
- Comparator arm alignment: head-to-head trials must harmonize titration duration or use a common run-in before the efficacy evaluation period.
- Sample size: higher early dropout during titration inflates required enrollment — use historical titration-completion rates in sample size calculations.
REMS and access context: No GLP-1 RA currently carries an FDA REMS. However, supply constraints, payer prior authorization, and step-therapy requirements create de facto access barriers that affect real-world uptake curves — distinct from but equally important to regulatory risk management for market access and HEOR teams.